The Ensign Group, Inc. (ENSG) Stock Price & Analysis
The Ensign Group, Inc. (ENSG) closed at USD 178.35 on Thursday, October 22, 2026, up 2.88% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 173.35; the Oct 22, 2026 session ranged USD 172.12–178.63 on volume of 307,787 shares. Market capitalization is $10.39B, with a 52-week range of USD 141.58–218 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:26 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ENSG.md
Key facts (ENSG)
- Last four reported quarters (through Jun 30, 2026): revenue $5.49B, net income $379M (6.9% margin) (SEC filings).
- Valuation: P/E 27.4x (avg 28.8x at the last 3 fiscal year-ends), EV/EBITDA 17.6x, net cash $181M.
- 1 of 80 tracked superinvestors hold ENSG (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 220 (range 207–230).
- Total return with dividends: 1Y -3.6% vs S&P 500 +14.9%; 5Y +149.8% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 1.97, revenue estimate $1.51B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ENSG)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.63B | $3.03B | $3.73B | $4.26B | $5.06B | $5.49B |
| Gross profit | $608M | $671M | $788M | $884M | $1.04B | — |
| Operating income | $260M | $297M | $255M | $358M | $425M | $467M |
| Net income | $195M | $225M | $209M | $298M | $344M | $379M |
| EPS (diluted) | $3.42 | $3.95 | $3.65 | $5.12 | $5.84 | — |
| Gross margin | 23.1% | 22.2% | 21.1% | 20.7% | 20.5% | — |
| Operating margin | 9.9% | 9.8% | 6.8% | 8.4% | 8.4% | 8.5% |
| Net margin | 7.4% | 7.4% | 5.6% | 7.0% | 6.8% | 6.9% |
| Revenue growth | +9.4% | +15.1% | +23.3% | +14.2% | +18.7% | — |
| Cash + short-term investments | $276M | $332M | $527M | $527M | $572M | — |
| Total debt | $160M | $156M | $152M | $148M | $144M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ENSG)
P/E 27.4x · P/S 1.9x · EV/EBITDA 17.6x · EV/Sales 1.9x · P/B 4.3x · Earnings yield 3.64% · Dividend yield (paid, TTM) 0.14% · Buyback yield (TTM) 0.38% · Net cash $181M · EV $10.2B
P/E at fiscal year-ends: Dec 2025 29.8x, Dec 2024 26.0x, Dec 2023 30.7x.
Superinvestors (SEC 13F-HR, Q2 2026) (ENSG)
1 of 80 tracked investors hold ENSG. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.02% | $10.4M | New position |
Analysts (ENSG)
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 220 (low 207, high 230).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-30 | Truist Securities | Target raised | Hold | $202 → $207 |
| 2026-07-14 | Truist Securities | Target lowered | Hold | $215 → $202 |
Total return (dividends reinvested) (ENSG)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -3.6% | +149.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -3.7% | +20.0% |
| Volatility (annualized) | 27.9% | 24.0% |
| Max drawdown | -31.8% (Mar 2026→Jun 2026) | -30.2% (Feb 2026→Jun 2026) |
Companies that name ENSG in their SEC reports
| Relationship to ENSG | Company | Filing | Sentence |
|---|---|---|---|
| partner | Pennant Group, Inc. (PNTG) | 10-K Feb 26, 2026 | “Pennant and Ensign continue to partner in the provision of services along the healthcare continuum.” |
ENSG analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.97 | $1.90 | +3.5% | $1.51B | 5 |
| Next quarter (ends Dec 2026) | $2.07 | $1.96 | +5.5% | $1.57B | 5 |
| Current fiscal year (ends Dec 2026) | $7.81 | $7.56 | +3.4% | $5.90B | 5 |
| Next fiscal year (ends Dec 2027) | $8.59 | $8.33 | +3.1% | $6.57B | 5 |
ENSG options: expected move
Options price a move of about ±8.0% (±$14.25) by Nov 20, 2026, which includes earnings on Nov 3, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 35.2% | ±8.0% |
| Dec 18, 2026 | 56 | 30.8% | ±9.7% |
| Mar 19, 2027 | 147 | 29.1% | ±14.8% |
| Jun 17, 2027 | 237 | 28.4% | ±18.4% |
30-day implied volatility 33% vs 21.8% realized over the last 30 trading days. Put/call ratio (volume) 0.03. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:26 UTC)
| Price | USD 178.35 |
|---|---|
| Change | ▲ 2.88% (up) |
| Previous Close | USD 173.35 |
| Open | USD 173.62 |
| Day Range | USD 172.12 – 178.63 |
| 52-Week Range | USD 141.58 – 218 |
| Volume | 307,787 shares |
| Market Cap | $10.39B |
| Exchange | NMS |
Technical Analysis (ENSG)
Nexqual's technical model rates ENSG "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:26 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 58.48 (neutral) |
| vs SMA50 | Above (USD 175.11) |
| MACD | 0.46 (positive) |
Analyst Ratings (ENSG)
Wall Street analysts rate ENSG "Buy" based on 5 analysts, with a mean price target of USD 220 (range USD 207–230), per Nexqual as of October 23, 2026 at 09:26 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 220 |
| High Target | USD 230 |
| Low Target | USD 207 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (ENSG)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 1.97 |
| Revenue Estimate | $1.51B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.92 vs est 1.85 ▲ beat |
| 2026-03-31 | USD 1.85 vs est 1.82 ▲ beat |
| 2025-12-31 | USD 1.82 vs est 1.77 ▲ beat |
| 2025-09-30 | USD 1.64 vs est 1.61 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financials & Fundamentals (ENSG)
| Total Revenue | $5.49B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +17.30% |
| Gross Margin | +16.57% |
| Operating Margin | +9.04% |
| Profit Margin | +6.90% |
| ROE | +16.97% |
| Debt / Equity | 0.92 |
| Current Ratio | 1.21 |
| Total Cash | $320.84M |
| Total Debt | $2.25B |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Ownership (ENSG)
| Insider Ownership | +3.54% |
|---|---|
| Institutional Ownership | +91.99% |
| Shares Outstanding | 58.28M |
| Float | 55.65M |
| Short % of Float | +3.01% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Leadership (ENSG)
The Ensign Group, Inc. is led by Barry R. Port, CEO & Chairman of the Board, per Nexqual as of October 23, 2026 at 09:26 UTC.
| CEO & Chairman of the Board | Barry R. Port |
|---|---|
| President & COO | Spencer W. Burton |
| CFO, Executive VP & Director | Suzanne D. Snapper |
| President of Keystone Healthcare Inc | Kevin Reese |
Major Backers & Investors (ENSG)
Notable institutional backers of The Ensign Group, Inc. include Baillie Gifford, FMR, LLC, Wasatch Advisors LP, according to Nexqual as of October 23, 2026 at 09:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baillie Gifford | 8.63% |
| FMR, LLC | 4.36% |
| Wasatch Advisors LP | 3.5% |
| Capital Group | 3.47% |
| SmallCap World Fund Inc | 3.37% |
| Arrowstreet Capital, Limited Partnership | 1.84% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.03% |
| Vanguard Group | 9.42% |
| State Street | 3.08% |
| Geode Capital | 2.86% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| UHS | Universal Health Services, Inc. | USD 188.13 | ▲ 2.88% |
| FMS | Fresenius Medical Care AG | USD 22.23 | ▲ 3.11% |
| DVA | DaVita Inc. | USD 186.1 | ▲ 5.25% |
| EHC | Encompass Health Corporation | USD 126.01 | ▲ 4.6% |
| PACS | PACS Group, Inc. | USD 47.5 | ▲ 1.58% |
| CHE | Chemed Corp | USD 520.15 | ▲ 1.72% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:26 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt